DUSA Pharmaceuticals, Inc. to Host Second Quarter Financial Results and Corporate Highlights Conference Call

For release at 8:00 a.m.

DUSA PHARMACEUTICALS, INC. TO HOST
SECOND QUARTER FINANCIAL RESULTS
AND CORPORATE HIGHLIGHTS CONFERENCE CALL

Wilmington, MA - August 2, 2007- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its corporate highlights and second quarter financial results press release will be issued on August 7, 2007 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

Tuesday, August 7, 2007 - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA

For International callers use
435.871.6103

A recorded replay of the call will be available
North American callers 877.863.0350
International callers 858.244.1268

The call will be accessible on our web site approximately 1 hour following the call at www.dusapharma.com.

About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or Grade 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach, Nicomide® and the AVAR® line. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.

For further information contact:
Shari Lovell, Director, Shareholder Services
Tel: 416.363.5059